Prostate cancer patients older than 70 years treated by radical prostatectomy have higher biochemical recurrence rate than their matched younger counterpart

Prostate

Volumn 73, Issue 8, 2013, Pages 897-903

  Ko, Jennifer ^a   Falzarano, Sara M ^a,b   Walker, Esteban ^a   Streator Smith, Karen ^a   Stephenson, Andrew J ^a   Klein, Eric A ^a   Magi Galluzzi, Cristina ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

age; biochemical failure; Gleason score; prostate cancer; radical prostatectomy

Indexed keywords

AGE DISTRIBUTION; AGED; ARTICLE; BIOCHEMISTRY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY;

AGE FACTORS; AGED; COHORT STUDIES; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 84876892424     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22635     Document Type: Article

References (29)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Kinsella K, He W,. An Aging World: 2008, (U. S. Census Bureau, I. P. R. P. -. Ed.). Washington, DC: U.S. Government Printing Office; 2009. https://www.census.gov/prod/2009pubs/p95-09-1.pdf
3. Brooks DD, Wolf A, Smith RA, Dash C, Guessous I,. Prostate cancer screening 2010: Updated recommendations from the American Cancer Society. J Natl Med Assoc 2010; 102: 423-429.
4. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen CM,. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007; 177: 2106-2131.
5. Screening for prostate cancer: US Preventive Task Force recommendation statement. US Preventive Services Task Force. Ann Internal Med 2008;149:185-191.
6. Stangelberger A, Waldert M, Djavan B,. Prostate cancer in elderly men. Rev Urol 2008; 10: 111-119.
7. Nguyen PL, Lipsitz SR, Choueiri TK, Gu X, Choi WW, Lei Y, D'Amico AV, Hu JC,. Time trends in the utilization of higher-cost treatments for prostate cancer: 2002-2007. ASCO 2010 Genitourinary Cancers Symposium (oral presentation).
8. Barbash GI, Glied SA,. New technology and health care costs-The case of robot-assisted surgery. N Engl J Med 2010; 363: 701-704.
9. Falzarano SM, Navas M, Simmerman K, Klein EA, Rubin MA, Zhou M, Magi-Galluzzi C,. ERG rearrangement is present in a subset of transition zone prostatic tumors. Mod Pathol 2010; 23: 1499-1506.
10. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A,. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974.
11. Karram S, Trock BJ, Netto GJ, Epstein JI,. Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings. Am J Surg Pathol 2011; 35: 1351-1355.
12. Pepe P, Candiano G, Fraggetta F, Galia A, Grasso G, Allegro R, Aragona F,. Is PSA density still useful in diagnosing prostate cancer ? Arch Ital Urol Androl 2009; 81: 199-202.
13. Bergstralh E, Kosanke J,. Computerized matching of cases to controls Technical Report Series No. 56 Department of Health Sciences Research, Mayo Clinic, Rochester, MN; 1995.
14. (2010) NCCN Clinical Practice Guidelines in Oncology. Prostate cancer, p http://www.nccn.org/professionals/physician-gls/PDF/prostate.pdf.
15. Abdollah F, Sun M, Thuret R, Jeldres C, Tian Z, Briganti A, Shariat SF, Perrotte P, Rigatti P, Montorsi F, Karakiewicz PI,. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. Eur Urol 2011; 59: 88-95.
16. Pfitzenmaier J, Pahernik S, Buse S, Haferkamp A, Djakovic N, Hohenfellner M,. Survival in prostate cancer patients> or = 70 years after radical prostatectomy and comparison to younger patients. World J Urol 2009; 27: 637-642.
17. Rice KR, Colombo ML, Wingate J, Chen Y, Cullen J, McLeod DG, Brassell SA,. Low risk prostate cancer in men >/= 70 years old: To treat or not to treat. Urol Oncol 2011 (Epub ahead of print) (PMID:21872499).
18. Richstone L, Bianco FJ, Shah HH, Kattan MW, Eastham JA, Scardino PT, Scherr DS,. Radical prostatectomy in men aged >or = 70 years: Effect of age on upgrading, upstaging, and the accuracy of a preoperative nomogram. BJU Int 2008; 101: 541-546.
19. Brassell SA, Rice KR, Parker PM, Chen Y, Farrell JS, Cullen J, McLeod DG,. Prostate cancer in men 70 years old or older, indolent or aggressive: Clinicopathological analysis and outcomes. J Urol 2011; 185: 132-137.
20. Kim JK, Cho SY, Jeong CW, Lee SB, Ku JH, Hong SK, Byun SS, Kwak C, Him HH, Lee SE, Jeong H,. Patients aged more than 70 had higher risk of locally advanced prostate cancers and biochemical recurrence in Korea. BJU Int 2012; 110: 505-509.
21. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL,. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 1228-1242.
22. Sun L, Caire AA, Robertson CN, George DJ, Polascik TJ, Maloney KE, Walther PJ, Stackhouse DA, Lack BD, Albala DM, Moul JW,. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. J Urol 2009; 182: 2242-2248.
23. Grossfeld GD, Chang JJ, Broering JM, Li YP, Lubeck DP, Flanders SC, Carroll PR,. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: Results from the Cancer of the prostate strategic urologic research endeavor database. J Urol 2001; 165: 851-856.
24. Falzarano SM, Magi-Galluzzi C,. Prostate cancer staging and grading at radical prostatectomy over time. Adv Anat Pathol 2011; 18: 159-164.
25. Ghani KR, Grigor K, Tulloch DN, Bollina PR, McNeill SA,. Trends in reporting Gleason score 1991 to 2001: Changes in the pathologist's practice. Eur Urol 2005; 47: 196-201.
26. Smith EB, Frierson HF Jr, Mills SE, Boyd JC, Theodorescu D,. Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: Is there evidence for systematic upgrading ? Cancer 2002; 94: 2282-2287.
27. Mullins JK, Han M, Pierorazio PM, Partin AW, Carter HB,. Radical prostatectomy outcome in men 65 years old or older with low risk prostate cancer. J Urol 2012; 187: 1620-1625.
28. Froehner M, Koch R, Litz RJ, Wirth MP,. Nomogram underestimates 10-year survival in healthy men selected for radical prostatectomy at age 70 years or older. Urology 2009; 73: 610-613; discussion 613-614.
29. Jeldres C, Suardi N, Walz J, Saad F, Hutterer GC, Bhojani N, Shariat SF, Perrotte P, Graefen M, Montorsi F, Karakiewicz PI,. Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: A population-based study of 6183 men. Eur Urol 2008; 54: 107-116.